Duration of Therapy: Clinical Trials

61 trials of Duration of Therapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

56 completed, 4 terminated, 1 withdrawn. 61 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 361Completed 56, Terminated 4, Withdrawn 1

Follow Duration of Therapy: new trials by email Literature Review of Duration of Therapy trials Research Report on Duration of Therapy

Trials (filtered) newest first · largest first

All 61 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of MK0524A on Flushing Caused by Niacin (0524A-056)
MK0524A, /Duration of Treatment : 4 Weeks, Comparator : niacin /Duration of Treatment : 1 Weeks - Flushing
Phase 3CompletedMerck Sharp & Dohme LLC3302007-04-012017-02-17
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)
MK0928 / Duration of Treatment : 8 Weeks - Primary Insomnia
Phase 3TerminatedH. Lundbeck A/S1382006-09-012015-01-14
Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)
MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks, Comparator: atorvastatin / Duration of Treatment: 6 Weeks - Cardiovascular Diseases, Diabetes Mellitus
Phase 3TerminatedOrganon and Co5502006-09-012024-08-15
Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children
Smecta (Diosmectite), duration of treatment - 7 days - Diarrhoea
Phase 3CompletedIpsen3022006-07-012019-11-22
Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children
Smecta (Diosmectite), duration of treatment - 7 days - Diarrhoea
Phase 3CompletedIpsen3002006-06-012019-11-22
An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)
MK0954, losartan potassium / Duration of Treatment - 12 weeks - Hypertension
Phase 3TerminatedOrganon and Co112006-03-132024-08-15
Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)
MK0991, caspofungin acetate / Duration of Treatment: - Fungal Infection
Phase 3CompletedMerck Sharp & Dohme LLC1312006-03-012015-12-17
Upper GI Handling of Branded vs. Generic Alendronate
MK0217, alendronate sodium / Duration of Treatment: 1 Month, Comparator: Alendronate-Teva / Duration of Treatment: 1 Month - Osteoporosis
Phase 3CompletedMerck Sharp & Dohme LLC252005-12-012006-11-17
SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)
MK0476, montelukast sodium / Duration of Treatment: 8 Weeks - Asthma
Phase 3CompletedOrganon and Co1982005-11-012024-08-15
Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)
MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks - Hypertension
Phase 3CompletedOrganon and Co622005-09-012024-08-15
To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)
MK0476, montelukast sodium / Duration of Treatment: 12 Weeks - Asthma
Phase 3CompletedOrganon and Co582005-08-012024-08-15
To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)
MK0826, ertapenem sodium / Duration of Treatment: 14 Days - Infection, Pneumonia
Phase 3CompletedMerck Sharp & Dohme LLC302005-07-012017-02-17
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)
MK0462, rizatriptan benzoate / Duration of Treatment -1 day, Comparator: placebo / Duration of Treatment - 1 day - Migraine
Phase 3CompletedOrganon and Co3932005-05-272024-08-14
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)
MK0462, rizatriptan benzoate / Duration of Treatment -1day, Comparator: placebo / Duration of Treatment - 1 day - Migraine
Phase 3CompletedOrganon and Co3932005-05-272024-08-14
Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)
MK0653, ezetimibe / Duration of Treatment: 4 Weeks - Hypercholesterolemia
Phase 3CompletedOrganon and Co4402005-04-012024-08-15
Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)
MK0653, ezetimibe / Duration of Treatment: 6 Weeks - Hypercholesterolemia
Phase 3CompletedOrganon and Co1412005-03-012024-05-10
Eze/Simva Switch Study in Diabetics (0653A-807)
MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks, Comparator: atorvastatin / Duration of Treatment: 6 Weeks - Diabetes Mellitus, Type 2
Phase 3CompletedOrganon and Co6482005-01-192024-08-15
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval - Acromegaly
Phase 3CompletedIpsen382005-01-012019-11-22
An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)
MK0928, gaboxadol / Duration of Treatment: 10 months - Insomnia
Phase 3WithdrawnH. Lundbeck A/S2005-01-012015-01-14
MK0954A-264 Filter Study (0954A-264)(COMPLETED)
MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks, losartan / Duration of Treatment: 6 weeks - Mild to Severe Hypertension
Phase 3CompletedOrganon and Co2742004-12-012024-08-15

Showing 20 of 61. Sign in to see all of them.

Conditions studied

Hypercholesterolemia (6)  ·  Hypertension (5)  ·  Asthma (4)  ·  Migraine Disorders (4)  ·  Osteoporosis (4)  ·  Osteoporosis, Postmenopausal (4)  ·  Sleep Initiation and Maintenance Disorders (4)  ·  Diabetes Mellitus, Type 2 (3)  ·  Acromegaly (2)  ·  Condylomata Acuminata (2)  ·  Coronary Disease (2)  ·  Diarrhea (2)  ·  Low Back Pain (2)  ·  Osteoarthritis (2)  ·  Uterine Cervical Neoplasms (2)

Sponsors

Organon and Co (38)  ·  Merck Sharp & Dohme LLC (15)  ·  H. Lundbeck A/S (4)  ·  Ipsen (4)

Countries

Germany (1)  ·  Italy (1)  ·  Malaysia (1)  ·  Peru (1)

Results publications

PMID 16291062, PMID 17196507, PMID 17502347, PMID 17985033, PMID 18922570, PMID 19059567, PMID 19236277, PMID 19236279, PMID 19332468, PMID 19487264, PMID 19505910, PMID 19542735, PMID 20001655, PMID 20191935, PMID 20200926, PMID 20589977, PMID 20601389, PMID 21086246, PMID 21239405, PMID 21300618, PMID 21304095, PMID 21307649, PMID 21358415, PMID 21720264, PMID 22243363, PMID 22695506, PMID 22753219, PMID 23062719, PMID 23403268, PMID 24379001, PMID 24723582, PMID 24798675, PMID 25340854, PMID 26056336, PMID 26089332, PMID 26378687, PMID 29151037, PMID 29176391, PMID 29474712, PMID 29580174, PMID 30676480, PMID 31926466, PMID 32184277, PMID 32586143, PMID 32586346, PMID 35213289, PMID 35345262, PMID 35525430

NIH funding

2004 (1)